Pro-Opiomelanocortin (POMC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Pro-Opiomelanocortin (POMC) Deficiency, a rare condition, manifests as monogenic obesity with severe early-onset obesity, adrenal insufficiency, red hair, and pale skin due to mutations in the POMC gene. This gene encodes the proopiomelanocortin protein, expressed in skin components such as melanocytes, keratinocytes, and dermal microvascular endothelial cells. The inheritance pattern is autosomal recessive. Glucocorticoids, CRH, and ultraviolet radiation control POMC expression. It is a prohormone for adrenocorticotropic hormone (ACTH), a crucial player in the adrenocortical response to stress. Promoter methylation regulates POMC expression, while in ACTH-dependent Cushing’s syndrome, the POMC gene is intrinsically activated. POMC consists of three segments: N-POMC (N-terminus), ACTH (middle), and β-LPH (C-terminus). Only about 50 cases of POMC deficiency have been documented in the medical literature.

Thelansis’s “Pro-Opiomelanocortin (POMC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pro-Opiomelanocortin (POMC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Pro-Opiomelanocortin (POMC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pro-Opiomelanocortin (POMC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Pro-Opiomelanocortin (POMC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Pro-Opiomelanocortin (POMC), Pro-Opiomelanocortin (POMC) market outlook, Pro-Opiomelanocortin (POMC) competitive landscape, Pro-Opiomelanocortin (POMC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)